Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Prior Breast Cancer and Survival in Patients with UPSC

Gynecol Oncol; ePub 2017 Jan 3; Pierce, Stine, et al

In women diagnosed with uterine papillary serous carcinoma (UPSC) and with a history of breast cancer (UPSCBR+), or with UPSC and without a history of breast cancer (UPSCBR-), a recent study found no difference in progression-free survival (PFS) and overall survival (OS). Furthermore, prior tamoxifen exposure was not associated with survival outcomes in patients with UPSC and breast cancer. Researchers also found:

  • Among 323 patients with UPSC, 46 (14%) were UPSCBR+; 15 (33%) of these had a history of tamoxifen use.
  • UPSCBR+ women demonstrated no significant differences in PFS or OS compared to UPSCBR- women, even after controlling for age.
  • There was no difference in PFS or OS with or without tamoxifen exposure within the UPSCBR+ cohort.

Citation:

Pierce SR, Stine JE, Gehrig PA, et al. Prior breast cancer and tamoxifen exposure does not influence outcomes in women with uterine papillary serous carcinoma. [Published online ahead of print January 3, 2017]. Gynecol Oncol. doi:10.1016/j.ygyno.2016.12.024.